Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 20/20 | 0.47 |
| ▸ | CDK9 | P50750 | 20/20 | 0.47 |
| ▸ | CDK4 | P11802 | 6/20 | 0.44 |
| ▸ | CCND1 | P24385 | 6/20 | 0.44 |
| ▸ | CDK7 | P50613 | 3/20 | 0.44 |
| ▸ | CCNH | P51946 | 3/20 | 0.44 |
| ▸ | CDK2 | P24941 | 4/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.42 |
| ▸ | CDK1 | P06493 | 3/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.42 |
| ▸ | CDK3 | Q00526 | 3/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31668065 | 0.86 | PRKAB2 (0.45) | CCNT1CDK9CDK4CCND1CDK7 | |
| SCHEMBL31668070 | 0.84 | CCNT1 (0.49) | CCNT1CDK9CDK4CCND1CDK7 | |
| SCHEMBL31668093 | 0.83 | CCNT1 (0.47) | CCNT1CDK9CDK4CCND1CDK7 | |
| SCHEMBL31668019 | 0.76 | ALDH1A1 (0.53) | — | |
| SCHEMBL31667963 | 0.73 | ALDH1A1 (0.34) | — | |
| SCHEMBL2033397 | 0.71 | KCNN3 (0.52) | CCNT1CDK9 | |
| SCHEMBL21946513 | 0.67 | CCNT1 (0.65) | CCNT1CDK9CDK4CCND1CDK7 | |
| SCHEMBL31668121 | 0.67 | ALDH1A1 (0.49) | — | |
| SCHEMBL18269476 | 0.65 | KDM4E (0.61) | — | |
| SCHEMBL21877682 | 0.64 | CCNT1 (0.82) | CCNT1CDK9CDK4CCND1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243208-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION | 2025-07-31 | — | — | US | claimed |
| US-20250243208-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243208-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | CCNT1 3974/4885CDK9 1629/4885CDK4 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.